<< Back to CME Activities
Show : Per page of 6

Updates and Best Practices Across Malignancies: Evaluating Therapeutic Developments and Optimizing Multidisciplinary Care in Non-Hodgkin’s Lymphoma

This virtually live educational activity focuses on leveraging targetable mutations for cancer-directed therapy through evaluating approaches to tumor assessment as well as the latest developments in novel targeted and immune-therapeutic approaches. Learn more about potential immune targets, systemic treatment strategies, and optimizing multidisciplinary management to individualize care in Non-Hodgkin’s Lymphoma.

RELEASED DATE: July 20, 2023
EXPIRATION DATE: July 20, 2024

Learn More & View Event »

Therapeutic Perspectives in Lymphoma Management: Current Considerations With Novel Bispecific Antibodies

STRIVE aims to create an initiative that HCPs can access to better define novel targets in the management of B-cell lymphomas, including bispecific antibodies and combinations under evaluation; summarize outcomes of key trials in B-cell lymphoma management, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma; and lastly to evaluate potential adverse events associated with novel therapies and best practices for management of adverse events in a multidisciplinary manner.

RELEASED DATE: November 22, 2022
EXPIRATION DATE: November 22, 2023

Learn More & View Event »

Evaluating the Latest Data in NHL: Contemporary Considerations with Novel Bispecific Antibodies

  • Contrast novel targets in NHL management, including consideration of the role of bispecific antibodies and combinations in development.
  • Evaluate outcomes of key trials in NHL management, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.
  • Summarize the current understanding potential adverse events associated with novel therapies, including considerations regarding multidisciplinary management of adverse events.

RELEASED DATE: January 25, 2023
EXPIRATION DATE: January 25, 2024

Learn More & View Event »

Current Considerations and Updates in NHL Management: The Emerging Role of Novel Bispecific Antibodies

This enduring summit meeting educational activity is designed for oncologists, hematologists, nurse practitioners, pharmacists, and other members of the multi-disciplinary oncology care team with the goal of increasing their: recognition of the role of bispecific antibodies in management of lymphoma, as well as clinical trial opportunities for patients with B-cell lymphomas; confidence discussing clinical trial outcomes with bispecific antibodies in lymphoma; awareness of specific adverse events associated with anti-CD20 therapies; and their recognition of multidisciplinary best practices for management of adverse events with targeted therapies for lymphoma.

RELEASED DATE: April 07, 2023
EXPIRATION DATE: April 07, 2024

Learn More & View Event »

Considerations for Emerging NHL Management: Contemporary Considerations in the Veterans Administration

This enduring program will focus on the treatment and management of Non-Hodgkin's lymphoma in the Veterans Affairs setting.

RELEASED DATE: November 22, 2022
EXPIRATION DATE: November 22, 2023

Learn More & View Event »

Community Practice Considerations:
Emerging Bispecific Antibodies in NHL

This educational activity is designed to evaluate novel targets in NHL management, including consideration of the role of bispecific antibodies and combinations in development; assess clinical outcomes of key trials in NHL management, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma and, lastly, to explain the current understanding of potential adverse events associated with novel therapies, including considerations regarding multidisciplinary management of adverse events.

RELEASED DATE: December 21, 2022
EXPIRATION DATE: December 21, 2023

Learn More & View Event »
Scroll to Top